Spinifex is a pioneer in the development of new treatments for chronic pain - a debilitating and often poorly treated condition affecting millions of patients worldwide. Demand for pain drugs continues to increase, fuelling the growth of a market that is expected to be worth over US$35 billion by 2017(1).

Spinifex’s lead programs are in neuropathic pain, a group of chronic painful conditions where the underlying cause is due to nerve dysfunction. Spinifex is also targeting inflammatory pain such as that caused by osteoarthritis. A significant opportunity exists for new candidates that can deliver improved efficacy, side effect profiles, time to onset and simplified dosing in chronic pain. EMA401, Spinifex’s lead clinical candidate, is being developed to address this unmet need and has successfully completed a Phase 2 clinical trial in postherpetic neuralgia (PHN), a neuropathic pain which follows herpes zoster (shingles) in some patients. In addition to PHN, EMA401 is being advanced as a potential treatment in other chronic pain indications and Spinifex has an active drug discovery program around its AT2 receptor antagonist technology.



(1) GBI Research. Pain Management Therapeutics Market to 2017 – Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta (November 2011).

Latest News & Events

29TH JUNE 2015 Spinifex Pharmaceuticals to be acquired by Novartis. US$200 million upfront payment plus undisclosed clinical development and regulatory milestones. More

17TH FEBRUARY 2015 Spinifex Pharmaceuticals Appoints Dr Peter Spargo as SVP, CMC and Dr Chris Richardson as Director CMC and Nonclinical Project Manager More

28TH MAY 2014 Spinifex Pharmaceuticals Strengthens Scientific Advisory Board (SAB) with Experts in Chronic Pain More